Avicanna Inc. (AVCNF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Avicanna Inc. (AVCNF) with AI Score 52/100 (Hold). Avicanna Inc. is a commercial-stage biopharmaceutical company focused on research, development, and commercialization of cannabinoid-based products. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Avicanna Inc. (AVCNF) Healthcare & Pipeline Overview
Avicanna Inc. is a Canadian biopharmaceutical company specializing in evidence-based cannabinoid products across medical, wellness, and pharmaceutical sectors. With a focus on research and development, Avicanna commercializes products under brands like RHO Phyto, Pura H&W, and Aureus, addressing diverse therapeutic areas and consumer needs in a competitive market.
Investment Thesis
Avicanna Inc. presents a compelling, albeit speculative, investment thesis centered on its diversified cannabinoid product portfolio and research-driven approach. With a market capitalization of $0.02 billion and a negative P/E ratio of -10.68, the company is currently unprofitable, but boasts a gross margin of 52.3%. Growth catalysts include the expansion of its product lines, particularly in pharmaceutical applications, and potential regulatory advancements in the cannabis industry. The company's research collaboration for COVID-19 treatment could provide significant upside. However, the company faces risks associated with operating in a highly regulated and competitive market, and its negative profit margin of -7.4% highlights the need for improved operational efficiency and revenue growth to achieve profitability and sustainable value creation.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.02 billion reflects the company's small size and growth potential in the biopharmaceutical sector.
- Gross Margin of 52.3% indicates strong pricing power and efficient production processes for its cannabinoid-based products.
- Negative P/E Ratio of -10.68 suggests the company is currently unprofitable, requiring investors to focus on future growth prospects.
- Beta of 0.26 indicates low volatility compared to the market, potentially appealing to risk-averse investors.
- Collaboration with Dr. Christine Allen's Research Group for COVID-19 treatment represents a significant opportunity for innovation and revenue generation.
Competitors & Peers
Strengths
- Strong focus on research and development.
- Diversified product portfolio across multiple segments.
- Established brands with customer recognition.
- Collaboration with reputable academic institutions.
Weaknesses
- Negative profit margin indicates financial challenges.
- Small market capitalization limits access to capital.
- Reliance on evolving cannabis regulations.
- Limited geographic reach compared to larger competitors.
Catalysts
- Upcoming: Potential regulatory approvals for cannabinoid-based pharmaceutical products.
- Ongoing: Expansion of distribution partnerships for RHO Phyto, Pura H&W, and Aureus brands.
- Ongoing: Progress in research collaboration for COVID-19 treatment.
- Upcoming: Positive clinical trial results for pharmaceutical product candidates.
Risks
- Potential: Intense competition from established pharmaceutical and cannabis companies.
- Potential: Changing cannabis regulations and potential restrictions.
- Potential: Risk of product recalls or safety concerns.
- Ongoing: Negative profit margin and financial challenges.
- Ongoing: Limited access to capital due to small market capitalization.
Growth Opportunities
- Expansion of Pharmaceutical Product Line: Avicanna has the opportunity to expand its pharmaceutical product line targeting conditions such as epidermolysis bullosa, dermatology issues, chronic pain, and neurological disorders. The global market for pain management alone is projected to reach $83 billion by 2027. Successful development and commercialization of these products could drive significant revenue growth.
- Increased Market Penetration of Wellness Brands: The Pura H&W and Pura Earth brands offer functional CBD consumer derma-cosmetic and topical products. The global CBD skincare market is expected to reach $3.48 billion by 2028. Increasing brand awareness and distribution through strategic partnerships could drive sales growth in this segment.
- Commercialization of COVID-19 Treatment: The research collaboration with Dr. Christine Allen's Research Group to develop a cannabinoid-based treatment for lung inflammation associated with COVID-19 represents a significant opportunity. If successful, this treatment could generate substantial revenue and enhance Avicanna's reputation as an innovative biopharmaceutical company.
- Geographic Expansion: Avicanna currently operates worldwide but has significant opportunity to expand its geographic reach, particularly in Europe and Latin America, where cannabis regulations are evolving. Entering new markets could diversify revenue streams and reduce reliance on existing markets.
- Strategic Partnerships and Acquisitions: Avicanna could pursue strategic partnerships or acquisitions to expand its product portfolio, access new technologies, or enter new markets. Collaborating with established pharmaceutical companies or acquiring complementary businesses could accelerate growth and enhance competitiveness.
Opportunities
- Expansion of pharmaceutical product line.
- Increased market penetration of wellness brands.
- Commercialization of COVID-19 treatment.
- Geographic expansion into new markets.
Threats
- Intense competition from established pharmaceutical and cannabis companies.
- Changing cannabis regulations and potential restrictions.
- Risk of product recalls or safety concerns.
- Economic downturn affecting consumer spending on wellness products.
Competitive Advantages
- Focus on evidence-based research and development provides a competitive advantage.
- Established brands like RHO Phyto, Pura H&W, and Aureus create brand recognition and customer loyalty.
- Collaboration with academic and medical institutions enhances credibility and scientific expertise.
- Diversified product portfolio across medical, wellness, and pharmaceutical segments reduces risk.
About AVCNF
Avicanna Inc., established in 2016 and headquartered in Toronto, Canada, is a commercial-stage biopharmaceutical company dedicated to the research, development, and commercialization of evidence-based cannabinoid-based products. The company operates across consumer medical and pharmaceutical segments globally, collaborating with Canadian academic and medical institutions to advance its scientific platform. Avicanna's portfolio includes approximately twenty products across four main market segments. These encompass medical and wellness products containing cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) under the RHO Phyto brand. It also offers functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names. Furthermore, the company provides cannabis dried flowers, standardized seeds, full-spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. Avicanna is also actively developing pharmaceutical products targeting conditions such as epidermolysis bullosa, dermatology issues, chronic pain, and various neurological disorders. A notable research collaboration with Dr. Christine Allen's Research Group focuses on developing a cannabinoid-based treatment for lung inflammation associated with COVID-19, highlighting the company's commitment to addressing critical healthcare needs.
What They Do
- Researches and develops evidence-based cannabinoid products.
- Commercializes products across medical, wellness, and pharmaceutical segments.
- Offers medical and wellness products under the RHO Phyto brand.
- Provides functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names.
- Supplies cannabis dried flowers, seeds, extracts, and distillates under the Aureus brand.
- Develops pharmaceutical products for conditions like epidermolysis bullosa and chronic pain.
- Collaborates with academic and medical institutions for research and development.
Business Model
- Develops and sells cannabinoid-based medical and wellness products.
- Generates revenue through direct sales and distribution partnerships.
- Focuses on research and development to create innovative products.
- Commercializes products under various brands targeting different market segments.
Industry Context
Avicanna Inc. operates within the rapidly evolving cannabis and biopharmaceutical industries. The global cannabis market is projected to reach billions of dollars in the coming years, driven by increasing legalization and acceptance of cannabis-based products for medical and recreational use. The competitive landscape includes established pharmaceutical companies, as well as emerging cannabis companies like Canopy Growth Corporation (CAAOF), Cronos Group (CNTMF), and Charlotte's Web Holdings (CWBHF). Avicanna differentiates itself through its focus on evidence-based research and development, aiming to create differentiated products with clinical validation.
Key Customers
- Patients seeking cannabinoid-based medical treatments.
- Consumers interested in CBD-based wellness and skincare products.
- Pharmaceutical companies seeking cannabinoid-based ingredients and formulations.
- Medical institutions and researchers.
Financials
Chart & Info
Avicanna Inc. (AVCNF) stock price: Price data unavailable
Latest News
-
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
GlobeNewswire · Mar 13, 2026
-
Stocks That Hit 52-Week Lows On Monday
· Dec 2, 2019
-
Stocks That Hit 52-Week Lows On Thursday
· Nov 14, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AVCNF.
Price Targets
Wall Street price target analysis for AVCNF.
MoonshotScore
What does this score mean?
The MoonshotScore rates AVCNF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Aras Azadian Mba
CEO
Aras Azadian is the CEO of Avicanna Inc. He possesses an MBA and has extensive experience in the healthcare and pharmaceutical industries. His background includes strategic leadership roles focused on business development, commercialization, and innovation. Azadian's expertise spans across various therapeutic areas, including dermatology, neurology, and pain management. He has a proven track record of driving growth and creating value in the biopharmaceutical sector.
Track Record: Under Aras Azadian's leadership, Avicanna Inc. has focused on expanding its product portfolio and strengthening its research and development capabilities. Key milestones include the launch of new products under the RHO Phyto, Pura H&W, and Aureus brands, as well as the establishment of strategic partnerships with academic and medical institutions. Azadian has also overseen the company's efforts to develop pharmaceutical products targeting various medical conditions.
AVCNF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Avicanna Inc. may not meet the minimum financial or reporting requirements of the higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries higher risk due to the potential for limited liquidity, price volatility, and lack of regulatory oversight compared to stocks listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower liquidity can lead to price volatility and difficulty exiting positions.
- Lack of regulatory oversight increases the risk of fraud or mismanagement.
- OTC Other stocks may be subject to delisting or trading suspensions.
- Potential for wider bid-ask spreads increases transaction costs.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Check for any news articles or reports that raise red flags.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before investing.
- Collaboration with Canadian academic and medical institutions.
- Focus on evidence-based research and development.
- Established brands like RHO Phyto, Pura H&W, and Aureus.
- Development of pharmaceutical products targeting specific medical conditions.
AVCNF Healthcare Stock FAQ
What does Avicanna Inc. do?
Avicanna Inc. is a biopharmaceutical company focused on the research, development, and commercialization of cannabinoid-based products. The company operates across medical, wellness, and pharmaceutical segments, offering products under brands like RHO Phyto, Pura H&W, and Aureus. Avicanna collaborates with academic and medical institutions to develop evidence-based treatments for various conditions, including chronic pain, dermatology issues, and neurological disorders. The company aims to establish itself as a leader in the cannabinoid-based pharmaceutical market.
What do analysts say about AVCNF stock?
AI analysis is pending for AVCNF. Generally, analysts will consider Avicanna's product pipeline, market opportunities, and financial performance when evaluating the stock. Key metrics include revenue growth, gross margin, and profitability. Analysts will also assess the company's competitive positioning and regulatory landscape. The stock's volatility and liquidity, particularly given its OTC listing, will also be considered. No buy or sell recommendations are available at this time.
What are the main risks for AVCNF?
Avicanna Inc. faces several risks, including intense competition from established pharmaceutical and cannabis companies, changing cannabis regulations, and potential product recalls. The company's negative profit margin and limited access to capital also pose significant challenges. Furthermore, the OTC listing increases risks related to liquidity, price volatility, and regulatory oversight. Investors should carefully consider these risks before investing in AVCNF.
What are the key factors to evaluate for AVCNF?
Avicanna Inc. (AVCNF) currently holds an AI score of 52/100, indicating moderate score. Key strength: Strong focus on research and development.. Primary risk to monitor: Potential: Intense competition from established pharmaceutical and cannabis companies.. This is not financial advice.
How frequently does AVCNF data refresh on this page?
AVCNF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AVCNF's recent stock price performance?
Recent price movement in Avicanna Inc. (AVCNF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong focus on research and development.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AVCNF overvalued or undervalued right now?
Determining whether Avicanna Inc. (AVCNF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AVCNF?
Before investing in Avicanna Inc. (AVCNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.
- Analyst opinions are not available at this time.
- OTC market investments carry higher risk than exchange-listed stocks.